Anti-tumor necrosis factor-α therapy in the management of psoriasis and B-chronic lymphocytic leukemia

Case Reports in Dermatology

Volumn 3, Issue 1, 2011, Pages 60-63

  Balato, Anna ^a   Lembo, Serena ^a   Cirillo, Teresa ^a   Megna, Matteo ^a   Raimondo, Annunziata ^a   Di Costanzo, Luisa ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Anti TNF drugs; B chronic lymphocytic leukemia; Psoriasis; Tumor necrosis factor

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; SALICYLIC ACID;

ADULT; ARTICLE; BODY SURFACE; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; HUMAN; LYMPHOCYTOSIS; PATIENT COMPLIANCE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; ULTRAVIOLET B RADIATION;

EID: 79957610759     PISSN: None     EISSN: 16626567     Source Type: Journal    
DOI: 10.1159/000324344     Document Type: Article

References (12)

1. Nestle FO, Kaplan DH, Barker J: Psoriasis. N Engl J Med 2009;361:496-509.
2. Sabat R, Philipp S, Hoflich C, Kreutzer S, Wallace E, Asadullah K, Volk HD, Sterry W, Wolk K: Immunopathogenesis of psoriasis. Exp Dermatol 2007;16:779-798. (Pubitemid 47377643)
3. Caldarola G, De Simone C, Carbone A, Tulli A, Amelio P, Feliciani C: TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept. Int J Immunopathol Pharmacol 2009;22:961-966.
4. Orlinick JR, Chao MV: TNF-related ligands and their receptors. Cell Signal 1998;10:543-551. (Pubitemid 28438330)
5. Gruss HJ, Dower SK: Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995;85:3378-3404.
6. Rozman C, Montserrat E: Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-1057.
7. Kolb JP, Kern C, Quiney C, Roman V, Billard C: Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr Drug Targets Cardiovasc Haematol Disord 2003;3:261-286. (Pubitemid 37540859)
8. Jetovic-Stoimenov T, Kocic G, Pavlovic D, Macukanovic-Golubovic L, Marjanovic G, Djordjevic V, Tosic N, Pavlovic S: Polymorphisms of tumor-necrosis factor-alpha -308 and lymphotoxin-alpha +250: possible modulation of susceptibility to apoptosis in chronic lymphocytic leukemia and non-Hodgkin lymphoma mononuclear cells. Leuk Lymphoma 2008;49:2163-2169.
9. Gallego A, Vargas JA, Castejon R, Citores MJ, Romero Y, Millan I, Durantez A: Production of intracellular IL2, TNFá and IFNã by T cells in B-CLL. Cytometry B Clin Cytom 2003;56:23-29. (Pubitemid 38292613)
10. Rosati E, Sabatini R, Tabilio A, Di Ianni M, Bartoli A, Marconi P: B chronic lymphocytic leukemia cells exert an in vitro cytotoxicity mediated by TNFá. Leuk Res 2005;29:829-839. (Pubitemid 40779490)
11. Waage A, Liabakk N, Lien E, Lamvik J, Espevik T: p55 and p75 tumor necrosis factor receptors in patients with chronic lymphocytic leukemia. Blood 1992;80:2577-2583.
12. Ferraioli A, Keating MJ, Taghi M, Gilles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O'Brien S, Albitar M: The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002;100:1215-1219. (Pubitemid 34864274)